Efficacy of two long-acting methylphenidate formulations in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting

Journal of Child and Adolescent Psychopharmacology

Volumn 15, Issue 4, 2005, Pages 637-654

  Silva, Raul ^a   Muniz, Rafael ^b   Pestreich, Linda K ^b   Brams, Matthew ^c   Childress, Ann ^d   Lopez, Frank A ^e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Bayou City Research   (United States)

^d Nevada Behavioral Health Inc   (United States)

^e Children's Developmental Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE;

AREA UNDER THE CURVE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; EXTENDED RELEASE FORMULATION; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; HYPERTENSION; LABORATORY; MAJOR CLINICAL STUDY; MALE; MATHEMATICS; MODIFIED RELEASE FORMULATION; MULTICENTER STUDY; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE BLIND PROCEDURE; STOMACH PAIN; SWANSON KOTKIN AGLER FLYNN AND PELHAM RATING SCALE; SYSTOLIC BLOOD PRESSURE; TASK PERFORMANCE; UNITED STATES;

AREA UNDER CURVE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MATHEMATICS; METHYLPHENIDATE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SAMPLE SIZE; SCHOOLS; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 26444609135     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2005.15.637     Document Type: Article

References (22)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision (DSM-IV-TR). Washington (DC), American Psychiatric Association, 2000.
2. Biederman J, Faraone S, Milberger S, Guite J, Mick E, Chen L, Mennin D, Marrs A, Ouellette C, Moore P, Spencer T, Norman D, Wilens T, Kraus I, Perrin J: A prospective 4-year follow-up study of attention-deficit/hyperactivity and related disorders. Arch Gen Psychiatry 53:437-446, 1996.
3. C-DISC: Diagnostic Interview Schedule for Children - generic DISC-IV. Version 7.01. New York, Columbia University, 1997.
4. Concerta LA (manufacturer's prescribing information): Mountain View, (CA), Alza Corporation, 2002.
5. Dalsgaard S, Mortensen PB, Frydenberg M, Thornsen PH: Conduct problems, gender and adult psychiatric outcome of children with attention-deficit/ hyperactivity disorder. Br J Psychiatry 181:416-421, 2002.
6. Gonzalez MA, Pentikis HS, Anderl N, Benedict MF, DeCory HH, Dirksen SJ, Hatch SJ: Methyl-phenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 40:175-184, 2002.
7. Guevara J, Lozano P, Wickizer T, Mell L, Gephart H: Psychotropic medication use in a population of children who have attention-deficit/ hyperactivity disorder. Pediatrics 109:733-739, 2002.
8. Hinshaw SP, Melnick SM: Peer relationships in boys with attention-deficit/hyperactivity disorder with and without comorbid aggression. Dev Psychopathol 7:627-647, 1995.
9. Hwang DS: Statistical examination of carryover effects in a 4 × 4 Latin square design (Williams design) using the baseline data (internal report). East Hanover, (NJ), Sandoz Pharmaceuticals Corporation, 1993.
10. Lesesne CA, Visser SN, White CP: Attention-deficit/hyperactivity disorder in school-aged children: Association with maternal mental health and use of health-care resources. Pediatrics 111:1232-1237, 2003.
11. Lopez F, Silva R, Pestreich L, Muniz R: Comparative efficacy of two once-daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention-deficit/hyper-activity disorder across the school day. Paediatr Drugs 5:545-555, 2003.
12. Markowitz JS, Straughn AB, Patrick KS, DeVane CL, Pestreich L, Lee J, Wang Y, Muniz R: Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet 42:393-401, 2003.
13. Ritalin LA (manufacturer's prescribing information). East Hanover, (NJ), Novartis Pharmaceuticals Corporation, 2003.
14. Robison LM, Sclar DA, Skaer TL, Galin RS: National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin Pediatr (Phila) 38:209-217, 1999.
15. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S: Pharmacotherapy of attention-deficit/hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409-432, 1996.
16. Swanson J, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, Williams L, Shoulson I, Wigal S: Acute tolerance to methylphenidate in the treatment of attention-deficit/hyperactivity disorder in children. Clin Pharmacol Ther 66:295-305, 1999.
17. Swanson J, Kinsbourne M, Roberts W, Zucker K: Time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics 61:21-29, 1978.
18. Swanson J, Wigal S, Greenhill L, Browne R, Waslick B, Lerner M, Williams L, Flynn D, Agler D, Crowley KL, Fineberg E, Regino R, Baren M, Cantwell D: Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 34:55-60, 1998.
19. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ, Comacs Study Group: A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 113:e206-e216, 2004.
20. Whalen CK, Henker B: The social profile of attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 1:395-410, 1992.
21. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G: Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108:883-892, 2001.
22. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F: Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283:1025-1030, 2000.